3 news items
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination
QLGN
30 May 24
condition, growth and strategies. Any or all of the forward-looking statements may turn out to be wrong or be affected by assumptions the Company makes
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented At American Association Of Cancer Research 2024 Annual Meeting
QLGN
10 Apr 24
at a promising therapeutic potential for Pan-RAS inhibitors in clinical settings, emphasizing their significance in cancer treatment strategies
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
QLGN
10 Apr 24
in clinical settings, emphasizing their significance in cancer treatment strategies. About Pan-RAS
- Prev
- 1
- Next